Advertisement

Lipids in Health and Disease

, 18:210 | Cite as

Triglyceride to high-density lipoprotein cholesterol ratio as a predictor of long-term mortality in patients with coronary artery disease after undergoing percutaneous coronary intervention: a retrospective cohort study

  • Xin-Ya Dai
  • Ying-Ying ZhengEmail author
  • Jun-Nan Tang
  • Xu-Ming Yang
  • Qian-Qian Guo
  • Jian-Chao Zhang
  • Meng-Die Cheng
  • Feng-Hua Song
  • Zhi-Yu Liu
  • Kai Wang
  • Li-Zhu Jiang
  • Lei Fan
  • Xiao-Ting Yue
  • Yan Bai
  • Zeng-Lei Zhang
  • Ru-Jie Zheng
  • Jin-Ying ZhangEmail author
Open Access
Research
Part of the following topical collections:
  1. Lipids as signaling molecules

Abstract

Background

It has been confirmed that the triglyceride to high-density lipoprotein cholesterol ratio (THR) is associated with insulin resistance and metabolic syndrome. However, to the best of our knowledge, only a few studies with small sample sizes have investigated the relationship between THR and coronary artery disease (CAD). Therefore, we aimed to assess the correlation between the THR and long-term mortality in patients with CAD after undergoing percutaneous coronary intervention (PCI) in our study that enrolled a large number of patients.

Methods

A total of 3269 post-PCI patients with CAD were enrolled in the CORFCHD-ZZ study from January 2013 to December 2017. The mean follow-up time was 37.59 ± 22.24 months. Patients were divided into two groups according to their THR value: the lower group (THR < 2.84, n = 1232) and the higher group (THR ≥ 2.84, n = 2037). The primary endpoint was long-term mortality, including all-cause mortality (ACM) and cardiac mortality (CM). The secondary endpoints were major adverse cardiac events (MACEs) and major adverse cardiac and cerebrovascular events (MACCEs).

Results

In our study, ACM occurred in 124 patients: 30 (2.4%) in the lower group and 94 (4.6%) in the higher group (P = 0.002). MACEs occurred in 362 patients: 111 (9.0%) in the lower group and 251 (12.3%) in the higher group (P = 0.003). The number of MACCEs was 482: 152 (12.3%) in the lower group and 320 (15.7%) in the higher group (P = 0.008). Heart failure occurred in 514 patients: 89 (7.2%) in the lower group and 425 (20.9%) in the higher group (P < 0.001). Kaplan–Meier analyses showed that elevated THR was significantly related to long-term ACM (log-rank, P = 0.044) and the occurrence of heart failure (log-rank, P < 0.001). Multivariate Cox regression analyses showed that the THR was an independent predictor of long-term ACM (adjusted HR = 2.042 [1.264–3.300], P = 0.004) and heart failure (adjusted HR = 1.700 [1.347–2.147], P < 0.001).

Conclusions

An increased THR is an independent predictor of long-term ACM and heart failure in post-PCI patients with CAD.

Keywords

Triglyceride to high-density lipoprotein cholesterol ratio Coronary artery disease Percutaneous coronary intervention All-cause mortality 

Abbreviations

ACM

All-cause mortality

CAD

Coronary artery disease

CIMT

Carotid intima-media thickness

CM

Cardiac mortality

HDL-C

High-density lipoprotein cholesterol

MACCEs

Major adverse cardiac and cerebrovascular events

MACEs

Major adverse cardiac events

PCI

Percutaneous coronary intervention

TG

Triglyceride

THR

Triglyceride to high-density lipoprotein cholesterol ratio

Background

Coronary artery disease (CAD) has been a major cause of mortality worldwide [1]. Some previous studies have shown that the pathological mechanisms of CAD include the nitric oxide pathway [2], inflammation response [3], estrogen deficiency [4], oxidation [5], thrombosis [6], and lipid metabolism [7]. In a study in 2013, Reiner Ž et al [8] found that 34.7% of patients with CAD had high triglyceride (TG) levels. Moreover, an ever-growing body of evidence has suggested that TG concentration is significantly associated with an increased risk of CAD [9]. In contrast, high-density lipoprotein cholesterol (HDL-C) levels were inversely related to morbidity in patients with CAD [10]. Furthermore, a study showed that 36.7% of patients with CAD had low HDL-C levels [8]. Some previous studies reported that the THR was associated with insulin resistance [11] and metabolic syndrome [12]. However, to our knowledge, there have been only a few studies reporting that the THR had a significant relationship with the extent of the lesion [13], cardiovascular events [14] and long-term ACM [15] in patients with CAD, whereas the sample sizes of these studies were small; none were more than 500 subjects. PCI is a common angioplasty method that is considered a useful therapy for patients with CAD. Some previous studies showed that PCI significantly improved the clinical outcome of patients with CAD [16, 17]. More recently, Sultani R et al. [15] performed a study in which a high THR independently predicted long-term ACM in 482 CAD patients who underwent coronary angiography without PCI. Therefore, we conducted a study with a larger sample size and aimed to assess whether there was an independent predictive value of an increased THR with regard to long-term mortality in patients with CAD who underwent PCI.

Methods

Study design and population

A total of 3561 patients were initially enrolled in our study; 292 patients were subsequently eliminated due to unavailable baseline TG or HDL-C data. Ultimately, there were 3269 eligible patients in our study. All of the abovementioned factors are shown in Fig. 1. All of the patients were from the Clinical Outcomes and Risk Factors of Patients with Coronary Heart Disease after PCI (CORFCHD-ZZ) study, the details of which could be browsed on http://www.chictr.org.cn (registration number: ChiCTR1800019699). The CORFCHD-ZZ study, which was a large, retrospective cohort study, included 3561 post-PCI patients with CAD admitted to the First Affiliated Hospital of Zhengzhou University from January 2013 to December 2017, and its data were obtained from case records and follow-ups. The inclusion criteria for eligibility in the current analysis were as follows: (1) patients aged at least 18 years; (2) at least one instance of coronary artery stenosis ≥50% confirmed by coronary angiography; (3) at least one clinical phenotype of coronary heart disease: stable angina or acute coronary syndrome; and (4) an indispensable and objective check for evidence of myocardial ischemia: positive stress test, FFR < 0.80 or OCT or IVUS examination suggesting unstable plaque. Patients with the following baseline characteristics were excluded: (1) younger than 18 or older than 80; (2) severe valvular heart disease; (3) severe congenital heart disease; (4) hyperthyroidism, anemia or other high-powered heart disease; (5) pulmonary heart disease; (6) hypertrophic obstructive cardiomyopathy; (7) liver dysfunction (defined as alanine aminotransferase or total bilirubin greater than 3 times the normal upper limit); (8) renal insufficiency (defined as serum creatinine greater than 1.5 times the normal upper limit); or (9) conditions with a high-risk of bleeding, such as thrombocytopenia, blood diseases and other diseases.
Fig. 1

A flowchart of the study design

Demographic, clinical and laboratory characteristics

The demographic, clinical and laboratory data were collected from the case records of inpatients at the First Affiliated Hospital of Zhengzhou University. The demographic and clinical data included gender, age, family history of CAD, medical history, hypertension, diabetes, smoking and alcohol consumption. CAD was defined as at least one clinical phenotype of coronary heart disease: stable angina or acute coronary syndrome and at least one instance of coronary artery stenosis ≥50% confirmed by coronary angiography. Hypertension was defined as a previously definitive diagnosis that referred to systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg by using at least three different blood pressure measurements in two disparate healthcare facilities according to the American Heart Association (AHA) Expert Consensus Document [18] or active use of anti-hypertensive drugs. Diabetes was defined as a previous definitive diagnosis that referred to fasting blood-glucose (FPG ≥ 7.0 mmol/L), two-hour postprandial glucose (2-h PG) > 11.1 mmol/L during an oral glucose tolerance test (OGTT) according to the American Diabetes Association (ADA) recommendations [19], or active use of hypoglycemic drugs. Smoking was defined as a previous smoking history or active smoking that referred to smoking day after day or every few days and having ever smoked more than 1 hundred cigarettes [20]. Alcohol drinkers were defined as patients who had consumed alcohol at least once before the study started [21].

The laboratory data included plasma and biochemical parameters such as the levels of TG, HDL-C, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), blood urea nitrogen (BUN), creatinine (Cr), uric acid (UA), glomerular filtration rate (GFR), glucose (GLU), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT). After fasting ≥12 h, blood samples were collected through a standard venipuncture technique before performing coronary angiography. Then, all blood samples were delivered into the central laboratory at the First Affiliated Hospital of Zhengzhou University.

Endpoints and follow-up

The primary endpoint was long-term mortality, including ACM and CM. The secondary endpoints were the composite of major adverse cardiac events (MACEs) and the composite of major adverse cardiac and cerebrovascular events (MACCEs). MACEs were defined as cardiac death, heart failure, bleeding events and readmission. MACCEs were defined as MACEs combined with stroke. Deaths were assumed to result from cardiac causes unless the fatal causes were definitively noncardiac [22]. The heart failure definition complied with the European Society Of Cardiology Guidelines (2016) for heart failure [23]. The definition of a bleeding event was in line with the Bleeding Academic Research Consortium Definition of Bleeding [24]. Readmission was defined as patients admitted to the hospital again, after discharge, due to symptoms or signs of angina pectoris. Stroke was defined as a sudden onset of vertigo, numbness, aphasia, or dysarthria resulting from vascular lesions of the brain, including hemorrhage, embolism, thrombosis, or rupturing aneurysm, and persisting more than 1 day [22].

The follow-up time was from 15 to 50 months, and its mean value was 37.59 ± 22.24 months. All investigators underwent standard training on the following: (1) method of follow-up: telephone interviews or office visits; (2) content of follow-up: complying with medical advice, the onset of endpoints and so on. The follow-up was conducted according to the above uniform criterion.

Statistical analysis

SPSS version 22.0 (SPSS Inc., Chicago, Illinois, United States) was utilized to analyze all data. Continuous variables were presented as the mean ± standard error and compared using t-tests (for data complying with a normal distribution) or Mann–Whitney U-tests (for data complying with a nonnormal distribution). Categorical variables were presented as frequencies and percentages and compared using the chi-square test. ROC curves were utilized to determine the cut-off value of the THR. The Kaplan–Meier method and the log-rank test were performed to estimate the cumulative incidences of long-term outcomes according to the THR (< 2.84 and ≥ 2.84). Multivariate Cox proportional hazards regression models were conducted to evaluate the independent predictive value of the THR with regard to long-term outcomes. All P-values < 0.05 were assumed to be significant.

Results

Baseline characteristics

In our study, the cut-off value for the baseline THR was 2.84 according to the analysis of the ROC curve. A total of 3269 post-PCI patients with CAD were divided into two groups according to the THR: the lower group (THR < 2.84, n = 1232) and the higher group (THR ≥ 2.84, n = 2037). In Table 1, we found that there were significant differences for several variables between the two groups, such as gender, smoking, age, Cr, UA, GLU, TC, TG, and HDL-C (all P < 0.05). However, the following variables were not significantly different between the two groups: family history; hypertension; diabetes; alcohol consumption; medications including calcium channel blocker (CCB), β-blockers, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB); systolic blood pressure (SBP); diastolic blood pressure (DBP); BUN; eGFR; ALT; AST; GGT and LDL-C (all P ≥ 0.05).
Table 1

Baseline characteristics of patients

Variables

THR < 2.84

THR ≥ 2.84

χ2 or t

P-Value

Gender, Male, n (%)

801 (65)

1450 (71.2)

13.615

< 0.001

Family history, n (%)

222 (18.1)

389 (19.3)

0.653

0.419

Hypertension, n (%)

687 (55.8)

1134 (55.7)

0.003

0.959

Diabetes, n (%)

284 (23.1)

491 (24.1)

0.470

0.493

Smoking, n (%)

348 (28.2)

649 (31.9)

4.730

0.030

Alcohol consumption, n (%)

192 (15.6)

348 (17.1)

1.252

0.263

CCB, n (%)

229 (18.6)

343 (16.8)

1.627

0.202

β- blocker, n (%)

595 (48.3)

1053 (51.7)

3.546

0.060

ACEI or ARB,n (%)

340 (27.6)

579 (28.4)

0.260

0.610

Age, years

64.02 ± 10.51

62.91 ± 10.62

2.903

0.004

SBP, mm Hg

133.25 ± 17.59

132.84 ± 18.07

0.619

0.536

DBP, mm Hg

78.67 ± 10.78

79.39 ± 11.41

−1.772

0.077

BUN, mmol/L

5.77 ± 5.26

5.76 ± 4.54

0.076

0.939

Cr, umol/L

70.08 ± 26.96

74.24 ± 46.35

− 2.863

0.004

UA, mmol/L

286.76 ± 86.07

304.38 ± 86.73

−5.614

< 0.001

eGFR,ml/Min

93.09 ± 27.59

91.08 ± 20.99

1.650

0.099

GLU, mmol/L

5.51 ± 2.05

5.75 ± 2.50

− 2.978

0.003

ALT,U/L

25 (16–42)

24 (16–40)

0.805

0.421

AST,U/L

22 (17–32)

21 (17–33)

0.126

0.990

GGT,U/L

24 (17–40)

25 (17–41)

0.257

0.797

TG, mmol/L

2.53 (1.33–3.83)

3.59 (2.85–4.84)

-8.797

< 0.001

TC, mmol/L

2.90 (1.42–3.88)

1.56 (1.08–2.63)

14.939

< 0.001

HDL-C, mmol/L

1.01 (0.85–1.21)

1.0 (0.86–1.18)

2.586

0.010

LDL-C, mmol/L

2.28 (1.77–2.86)

2.28 (1.81–2.90)

-1.342

0.180

Data presented as median (interquartile range) or mean ± SD or n (%). Abbreviation: THR Triglyceride to high-density lipoprotein cholesterol ratio, CCB Calcium channel blocker, ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker, SBP Systolic blood pressure, DBP Diastolic blood pressure, BUN Blood urea nitrogen, Cr Creatinine, UA Uric acid, GFR Glomerular filtration rate, GLU Glucose, ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transpeptidase, TG Triglyceride, TC Total cholesterol, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol. Note: The boldfaced P-Values are statistically different

Outcomes

As shown in Table 2, the incidence of ACM (2.4% versus 4.6%, P = 0.002), MACEs (9.0% versus 12.3%, P = 0.003), MACCEs (12.3% versus 15.7%, P = 0.008) and heart failure (7.2% versus 20.9%, P < 0.001) was significantly different between the two groups but CM was not (1.7% versus 2.7%, P = 0.067). Furthermore, as shown in Table 3, Fig. 2 and Fig. 3, the Kaplan–Meier analyses showed that an elevated THR was significantly related to long-term ACM (log-rank, P = 0.044) and the occurrence of heart failure (log-rank, P < 0.001). Multivariate Cox proportional hazards regression models were conducted to evaluate the correlation between the THR and outcomes; the models were adjusted for confounders including age, gender, family history, hypertension, diabetes, smoking, alcohol consumption, Cr, UA, and TC. Patients in the higher THR group had an elevated long-term ACM (adjusted HR = 2.042 [1.264–3.300], P = 0.004) and heart failure incidence (adjusted HR = 1.700 [1.347–2.147], P < 0.001), after being adjusted for several confounders, compared to patients in the lower THR group. Therefore, the increased THR had an independently predictive value for long-term ACM and heart failure. In addition, confounders of long-term ACM and heart failure are shown in Table 4 and Table 5.
Table 2

Outcomes comparison between groups

Outcomes

THR < 2.84

THR ≥ 2.84

χ2

P-Value

ACM, n (%)

30 (2.4%)

94 (4.6%)

9.993

0.002

CM, n(%)

21 (1.7%)

55 (2.7%)

3.35

0.067

MACEs, n (%)

111 (9.0%)

251 (12.3%)

8.553

0.003

MACCEs, n (%)

152 (12.3%)

320 (15.7%)

7.065

0.008

Heart failure, n(%)

89 (7.2%)

425 (20.9%)

107.785

< 0.001

Bleeding, n (%)

13 (1.1%)

13 (0.6%)

1.692

0.193

readmission, n (%)

360 (29.2%)

605 (29.7%)

0.085

0.771

Stroke, n (%)

46 (3.7%)

77 (3.8%)

0.005

0.946

Abbreviation: THR Triglyceride to high-density lipoprotein cholesterol ratio, ACM All-cause mortality, CM Cardiac mortality, MACEs Major adverse cardiovascular events, MACCEs Major adverse cardiovascular and cerebrovascular events. Note: The boldfaced P-Values are statistically different

Table 3

Incidence of outcomes on multivariate Cox proportional hazards regression models and log-rank test

Outcomes

HR

(95% CI)

P-Value

Adjusted HR

(95% CI)a

P-Value

log-rank test

χ2

P-Value

ACM

1.521 (1.007–2.299)

0.046

2.042 (1.264–3.300)

0.004

4.039

0.044

CM

1.264 (0.762–2.094)

0.364

1.707 (0.952–3.061)

0.072

0.830

0.362

MACEs

1.073 (0.857–1.344)

0.540

1.143 (0.898–1.456)

0.277

0.378

0.539

Heart failure

1.912 (1.519–2.406)

< 0.001

1.700 (1.347–2.147)

< 0.001

32.172

< 0.001

MACCEs

0.973 (0.801–1.182)

0.784

1.023 (0.832–1.260)

0.827

0.076

0.783

Abbreviation: THR Triglyceride to high-density lipoprotein cholesterol ratio, ACM All-cause mortality, CM Cardiac mortality, MACEs Major Adverse cardiovascular events including cardiac death, bleeding events, readmission, MACCEs Major adverse cardiovascular and cerebrovascular events including MACEs and stroke. Note: The boldfaced P-Values are statistically different

aAdjusted for age, gender, family history, hypertension, diabetes, smoking, alcohol consumption, creatinine, uric acid, and total cholesterol

Fig. 2

Cumulative Kaplan-Meier estimates of the time to the first adjudicated occurrence of all-cause mortality

Fig. 3

Cumulative Kaplan-Meier estimates of the time to the first adjudicated occurrence of heart failure

Table 4

Cox regression analysis results for long-term ACM

Variables

B

SE

Wald

P-Value

HR

95%CI

Age

0.066

0.010

41.202

< 0.001

1.069

1.047–1.091

Gender

− 0.175

0.256

0.466

0.495

0.840

0.508–1.387

Family history

−1.254

0.395

10.089

0.001

0.285

0.132–0.619

Hypertension

0.234

0.211

1.228

0.268

1.263

0.836–1.909

Diabetes

0.582

0.208

7.823

0.005

1.790

1.190–2.692

Smoking

0.102

0.284

0.128

0.721

1.107

0.635–1.930

Alcohol consumption

0.323

0.313

1.066

0.302

1.381

0.748–2.548

Cr

0.006

0.001

31.712

< 0.001

1.006

1.004–1.008

UA

0.001

0.001

0.427

0.513

1.001

0.999–1.003

TC

0.052

0.073

0.515

0.473

1.054

0.913–1.216

THR

0.714

0.245

8.513

0.004

2.042

1.264–3.300

Abbreviation: ACM All-cause mortality, Cr Creatinine, UA Uric acid, TC Total cholesterol, THR Triglyceride to high-density lipoprotein cholesterol ratio. Note: The boldfaced P-Values are statistically different

Table 5

Cox regression analysis results for heart failure

Variables

B

SE

Wald

P-Value

HR

95%CI

Age

0.002

0.004

0.266

0.606

1.002

0.994–1.011

Gender

0.156

0.112

1.912

0.167

1.168

0.937–1.456

Family history

−0.419

0.130

10.137

0.001

0.658

0.510–0.849

Hypertension

−0.047

0.093

0.262

0.609

0.954

0.796–1.143

Diabetes

0.151

0.106

2.028

0.154

1.163

0.945–1.432

Smoking

−0.054

0.127

0.182

0.669

0.947

0.739–1.214

Alcohol consumption

−0.217

0.156

1.943

0.163

0.805

0.593–1.092

Cr

0.002

0.001

5.298

0.021

1.002

1.000–1.005

UA

0.001

0.001

0.832

0.362

1.001

0.999–1.002

TC

−0.250

0.046

29.633

< 0.001

0.779

0.712–0.852

THR

0.531

0.119

19.932

< 0.001

1.700

1.347–2.147

Abbreviation: Cr Creatinine, UA Uric acid, TC Total cholesterol, THR Triglyceride to high-density lipoprotein cholesterol ratio. Note: The boldfaced P-Values are statistically different

Discussion

In our study, we found that an increased THR was an independent predictor of long-term ACM in post-PCI patients with CAD. Similarly, several studies demonstrated that the THR had a significant relationship with the extent of the lesions [13], cardiovascular events [14] and long-term ACM [15] of CAD, whereas the sample size of these studies was small; none were more than 500. Although a previous study reported that an elevated THR indicated the extent of CAD [13], there were no similar analyses related to the prognosis of CAD aside from our study. Ke Wan et al. [14] demonstrated that an increased THR raised the risk of cardiovascular events in CAD patients; however, compared to our study, the analysis method for determining the THR cut-off value was different, and their study had a smaller sample size (416 enrolled patients). Furthermore, in a study enrolling 482 patients, an increased THR had a significantly predictive value for long-term ACM in CAD patients [15], whereas there was no related comparison of MACCEs between the groups as was done in our study. In addition, a large number of patients were taking medications in our study, and we found that there was no significant difference with respect to the effect of medication use on the THR level in both groups (Table 1). Moreover, the Reduction of Atherothrombosis for Continued Health (REACH) study [25] showed that the use of ACEI/ARBs was not associated with the reduced incidence of adverse endpoints in stable CAD outpatients without HF. Similarly, the use of β-blockers did not significantly reduce the risk of composite cardiovascular events in CAD patients [26].

In a previous study conducted in a Chinese population, the THR had a powerfully predictive value for insulin resistance but not β cell function in patients who had various glucose tolerance statuses [11], and insulin resistance raised the incidence of CAD in patients with type 1 and type 2 diabetes mellitus [27]. Moreover, the THR had a definitive clinical usefulness for indicating the onset of metabolic syndrome [12], which was considered a precursor for the progression of CAD [28]. In addition, the THR was also an independent predictor for the development of arterial stiffness in normotensive patients [29] and was reported to be associated with early signs of structural vascular damage, such as elevated carotid intima-media thickness (CIMT), in children and adolescents [30]. Several studies showed that arterial stiffness and elevated CIMT predicted the increased incidence of CAD [31, 32].

There was an inverse correlation between the TG and HDL-C levels in CAD patients; in other words, the HDL-C level in plasma was lower in CAD patients with hypertriglyceridemia [33]. Furthermore, some previous studies demonstrated that high small dense LDL-C levels were significantly related to increased TG concentrations in patients with metabolic syndrome [34] and with reduced HDL-C levels in prediabetic patients [35]. In addition, the THR was also favorable for assessing the presence of small dense LDL-C, whereas it was more difficult and costly to detect small dense LDL-C than THR [36]. Therefore, it was feasible that the elevated THR was utilized as an alternative biomarker indicating increased small dense LDL-C [36], which was significantly associated with the incidence of adverse cardiovascular outcomes in CAD patients [37].

Study limitations

In our study, there were several limitations. First, due to a shortage of registered patients, some outcomes were not significantly different, such as CM, MACEs and MACCEs. Second, baseline TG and HDL-C levels were unavailable from a small number of patients enrolled in the CORFCHD-ZZ study, which added to the reduction of the sample size. Third, the follow-up data collection was incomplete. Last but not least, this study was retrospective and aimed to assess the correlation between the THR and long-term mortality in a Chinese patient population with CAD who underwent PCI. Therefore, the findings in our study need to be further demonstrated in different populations.

Conclusions

An increased THR was an independent predictor of long-term ACM and heart failure in post-PCI patients with CAD. Moreover, the THR is worth utilizing in clinical practice because it is a precise biomarker that is easily detected at a low cost.

Notes

Acknowledgements

The authors are grateful to the Department of Cardiology at the First Affiliated Hospital of Zhengzhou University for their help and expertise in conducting this study.

Authors’ contributions

XYD and YYZ made substantial contributions to study conception and design and to the drafting and critical revision of the manuscript for important intellectual content. JNT and XMY made substantial contributions to the study conception and design and critical revision of the manuscript for important intellectual content. QQG, JCZ, MDC, FHS, ZYL, KW, LZJ, LF, XTY, YB, ZLZ, RJZ participated in the collecting and analyzing of the data, writing and reviewing the manuscript. JYZ made substantial contributions to study conception and design, drafting and critical revision of the manuscript for important intellectual content, including study supervision. All authors read and approved the final manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (81870328, 81760043 and 81800267).

Ethics approval and consent to participate

This study protocol was approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University, and was in line with the Declaration of Helsinki. Due to the retrospective design of the study, the need to obtain informed consent from eligible patients was waived by the ethics committee.

Consent for publication

Written informed consent for publication was obtained from each author, and there are no other persons who satisfy the criteria for authorship but are not listed.

Competing interests

The authors declare that they have no competing interests.

References

  1. 1.
    Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–128.CrossRefGoogle Scholar
  2. 2.
    Kolasińska-Kloch W, Leśniak W, Kieć-Wilk B, et al. Biochemical parameters of endothelial dysfunction in cardiological syndrome X. Scand J Clin Lab Invest. 2002;62(1):7–13.CrossRefGoogle Scholar
  3. 3.
    Cosín-Sales J, Pizzi C, Brown S, et al. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol. 2003;41(9):1468–74.CrossRefGoogle Scholar
  4. 4.
    Kaski JC. Cardiac syndrome X in women: the role of oestrogen deficiency. Heart. 2006;92(Suppl 3):iii5–9.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54(1):24–38.CrossRefGoogle Scholar
  6. 6.
    Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104(3):365–72.CrossRefGoogle Scholar
  7. 7.
    Reiner Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14(7):401–11.CrossRefGoogle Scholar
  8. 8.
    Reiner Ž, De Bacquer D, Kotseva K, et al. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis. 2013;231(2):300–7.CrossRefGoogle Scholar
  9. 9.
    Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–8.CrossRefGoogle Scholar
  10. 10.
    Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301–10.CrossRefGoogle Scholar
  11. 11.
    Zhou M, Zhu L, Cui X, et al. The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of insulin resistance but not of β cell function in a Chinese population with different glucose tolerance status. Lipids Health Dis. 2016;15:104.CrossRefGoogle Scholar
  12. 12.
    Gasevic D, Frohlich J, Mancini GJ, et al. Clinical usefulness of lipid ratios to identify men and women with metabolic syndrome: a cross-sectional study. Lipids Health Dis. 2014;13:159.CrossRefGoogle Scholar
  13. 13.
    da Luz PL, Favarato D, Faria-Neto JR Jr, et al. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo). 2008;63(4):427–32.CrossRefGoogle Scholar
  14. 14.
    Wan K, Zhao J, Huang H, et al. The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization. PLoS One. 2015;10(4):e0123521.CrossRefGoogle Scholar
  15. 15.
    Sultani R, Tong DC, Peverelle M, et al. Elevated Triglycerides to High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio Predicts Long-Term Mortality in High-Risk Patients. Heart Lung Circ. 2019;(19):30334–8.Google Scholar
  16. 16.
    Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359(7):677–87.CrossRefGoogle Scholar
  17. 17.
    Piccolo R, Giustino G, Mehran R, et al. Stable coronary artery disease: revascularisation and invasive strategies. Lancet. 2015;386(9994):702–13.CrossRefGoogle Scholar
  18. 18.
    Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. Circulation. 2011;123(21):2434–506.CrossRefGoogle Scholar
  19. 19.
    American Diabetes Association. 2 Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–27.CrossRefGoogle Scholar
  20. 20.
    Kim HK, Lee TK. Conditional effects of gain-loss-framed narratives among current smokers at different stages of change. J Health Commun. 2017;22(12):990–8.CrossRefGoogle Scholar
  21. 21.
    Cho Y, Kwak S, Lewis SJ, et al. Exploring the utility of alcohol flushing as an instrumental variable for alcohol intake in Koreans. Sci Rep. 2018;8(1):458.CrossRefGoogle Scholar
  22. 22.
    Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med. 2011;364(18):1718–27.CrossRefGoogle Scholar
  23. 23.
    Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.CrossRefGoogle Scholar
  24. 24.
    Ndrepepa G, Schuster T, Hadamitzky M, et al. Validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012;125(11):1424–31.CrossRefGoogle Scholar
  25. 25.
    Sorbets E, Labreuche J, Simon T, et al. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. Eur Heart J. 2014;35(26):1760–8.CrossRefGoogle Scholar
  26. 26.
    Bangalore S, Steg G, Deedwania P, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340–9.CrossRefGoogle Scholar
  27. 27.
    Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293–302.CrossRefGoogle Scholar
  28. 28.
    Kastorini CM, Panagiotakos DB, Georgousopoulou EN, et al. Metabolic syndrome and 10-year cardiovascular disease incidence: the ATTICA study. Nutr Metab Cardiovasc Dis. 2016;26(3):223–31.CrossRefGoogle Scholar
  29. 29.
    Li G, Wu HK, Wu XW, et al. Small dense low density lipoprotein-cholesterol and cholesterol ratios to predict arterial stiffness progression in normotensive subjects over a 5-year period. Lipids Health Dis 2018;17(1):27.Google Scholar
  30. 30.
    Pacifico L, Bonci E, Andreoli G, et al. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr Metab Cardiovasc Dis. 2014;24(7):737–43.CrossRefGoogle Scholar
  31. 31.
    Vasan RS, Short MI, Niiranen TJ, et al. Interrelations between arterial stiffness, target organ damage, and cardiovascular disease outcomes. J Am Heart Assoc. 2019;8(14):e012141.CrossRefGoogle Scholar
  32. 32.
    Gepner AD, Young R, Delaney JA, et al. Comparison of coronary artery calcium presence, carotid plaque presence, and carotid intima-media thickness for cardiovascular disease prediction in the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2015;8(1).Google Scholar
  33. 33.
    Avogaro P, Ghiselli G, Soldan S, et al. Relationship of triglycerides and HDL cholesterol in hypertriglyceridemia. Atherosclerosis. 1992;92(1):79–86.CrossRefGoogle Scholar
  34. 34.
    Cho Y, Lee SG, Jee SH, et al. Hypertriglyceridemia is a major factor associated with elevated levels of small dense LDL cholesterol in patients with metabolic syndrome. Ann Lab Med. 2015;35(6):586–94.CrossRefGoogle Scholar
  35. 35.
    Hsu H, Hsu P, Cheng MH, et al. Lipoprotein subfractions and glucose homeostasis in Prediabetes and diabetes in Taiwan. J Atheroscler Thromb. 2019;26(10):890–914.CrossRefGoogle Scholar
  36. 36.
    Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb. 2003;10(3):186–91.CrossRefGoogle Scholar
  37. 37.
    Arsenault BJ, Lemieux I, Després JP, et al. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. Eur Heart J. 2007;28(22):2770–7.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Xin-Ya Dai
    • 1
    • 2
  • Ying-Ying Zheng
    • 1
    • 2
    Email author
  • Jun-Nan Tang
    • 1
    • 2
  • Xu-Ming Yang
    • 3
  • Qian-Qian Guo
    • 1
    • 2
  • Jian-Chao Zhang
    • 1
    • 2
  • Meng-Die Cheng
    • 1
    • 2
  • Feng-Hua Song
    • 1
    • 2
  • Zhi-Yu Liu
    • 1
    • 2
  • Kai Wang
    • 1
    • 2
  • Li-Zhu Jiang
    • 1
    • 2
  • Lei Fan
    • 1
    • 2
  • Xiao-Ting Yue
    • 1
    • 2
  • Yan Bai
    • 1
    • 2
  • Zeng-Lei Zhang
    • 1
    • 2
  • Ru-Jie Zheng
    • 1
    • 2
  • Jin-Ying Zhang
    • 1
    • 2
    Email author
  1. 1.Department of CardiologyFirst Affiliated Hospital of Zhengzhou UniversityZhengzhouPeople’s Republic of China
  2. 2.Key Laboratory of Cardiac Injury and Repair of Henan ProvinceZhengzhouPeople’s Republic of China
  3. 3.Department of CardiologyThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and TechnologyLuoyangPeople’s Republic of China

Personalised recommendations